Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-BCMA-CAR-IL15 NK cells
- Development stage
- Preclinical
- Lead developer
- University of Ottawa
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
α-BCMA-CAR-IL15 NK cells is an allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy engineered to express a CAR targeting B-cell maturation antigen (BCMA) along with interleukin-15 (IL-15) co-expression. Developed by researchers at the University of Ottawa, National Research Council Canada, Korea Institute of Science and Technology (KIST), and McMaster University, this cell therapy is designed to treat multiple myeloma. The co-expression of IL-15 is critical for the persistence and therapeutic efficacy of the CAR-NK cells. In preclinical models, the therapy demonstrated potent cytotoxicity and sustained elimination of multiple myeloma in the bone marrow, although it showed limited efficacy against extramedullary disease.
- Other names
- anti-BCMA-CAR-IL15 NK cellsanti-BCMA-CAR-IL-15 NK cellsanti-BCMA-CAR-IL 15 NK cellsα-BCMA-CAR-IL15 NKα-BCMA-CAR-IL15 cells
02
Targets
BCMA (B-cell maturation antigen)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on α-BCMA-CAR-IL15 NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on α-BCMA-CAR-IL15 NK cells.